Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Donadio

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinomaP F Conte, M Bruzzone, F Carnino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?M Ardine, D Generali, M Donadio, et al.
Academic Radiology|July 31, 2018
Comparison of Resource Utilization and Clinical Outcomes Following Screening with Digital Breast Tomosynthesis Versus Digital Mammography: Findings From a Learning Health SystemNila H Alsheik, Firas Dabbous, Scott K Pohlman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative GroupG Bonadonna, M Zambetti, C Bumma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2013
A simple and reproducible prognostic index in luminal ER-positive breast cancersI Castellano, L Chiusa, A M Vandone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinomaD Katsaros, M V Oletti, I A Rigault de la Longrais, et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology|January 22, 2011
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jawsP G Arduino, E Menegatti, M Scoletta, et al.
Oncology|December 2, 2005
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanesM Donadio, M Ardine, A Berruti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclinesA Berruti, P Sperone, A Bottini, et al.
Cancer Chemotherapy and Pharmacology|June 8, 2001
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trialM Donadio, E Manzin, A Berruti, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinomaP F Conte, M Bruzzone, F Carnino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2006
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?M Ardine, D Generali, M Donadio, et al.
Academic Radiology|July 31, 2018
Comparison of Resource Utilization and Clinical Outcomes Following Screening with Digital Breast Tomosynthesis Versus Digital Mammography: Findings From a Learning Health SystemNila H Alsheik, Firas Dabbous, Scott K Pohlman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative GroupG Bonadonna, M Zambetti, C Bumma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2013
A simple and reproducible prognostic index in luminal ER-positive breast cancersI Castellano, L Chiusa, A M Vandone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinomaD Katsaros, M V Oletti, I A Rigault de la Longrais, et al.
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology|January 22, 2011
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jawsP G Arduino, E Menegatti, M Scoletta, et al.
Oncology|December 2, 2005
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanesM Donadio, M Ardine, A Berruti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2000
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclinesA Berruti, P Sperone, A Bottini, et al.
Cancer Chemotherapy and Pharmacology|June 8, 2001
Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trialM Donadio, E Manzin, A Berruti, et al.
Pageof 6